Search

Displaying results 3751 - 3760 of 9670 in total
  1. Drug

    ADH-1

    go.drugbank.com/drugs/DB05485
    Investigational

    Poorly differentiated, highly invasive carcinomas are characterized by over-expression of N-cadherin (as opposed to E-cadherin). … As many tumors become more aggressive, invasive, and malignant, researchers have found that N-cadherin is expressed in greater amounts, making it an important target for developing anti-cancer treatments

  2. Drug

    V1003

    go.drugbank.com/drugs/DB05046
    Experimental

    prior to discharge from hospital and at home during their recovery period. … Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both

  3. Drug

    Albinterferon Alfa-2B

    go.drugbank.com/drugs/DB05396
    Investigational

    The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. … Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C.

  4. Drug

    2,4-Dinitrophenol

    go.drugbank.com/drugs/DB04528
    Experimental

    It is also used as a metabolic stimulant. (Stedman, 26th ed) … A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation.

  5. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.

  6. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    It was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults with rifampicin-susceptible pulmonary tuberculosis in a recruiting … Additionally, RESP301 was investigated in a withdrawn trial (NCT04842331) for preventing viral exposure and transmission of COVID-19 and in a not yet recruiting trial (NCT04386070) for preventing pulmonary

  7. Drug

    R-30490

    go.drugbank.com/drugs/DB09179
    Experimental

    It was first synthesized by Janssen Pharmaceutica as part of a structure-activity relationship study of fentanly and its derivatives. … R-30490 was found to be the most selective agonist for the mu opioid receptor out of all the fentanyl analogues tested, but it has never been introduced for medical use in humans, although the closely

  8. Drug

    Altropane

    go.drugbank.com/drugs/DB04947
    Investigational

    Boston Life Sciences (BLS) is developing Altropane as a potential radio-imaging agent to be used with single photon emission tomography (SPECT), for the early diagnosis of Parkinson's disease (PD) and

  9. Drug

    Deanol

    go.drugbank.com/drugs/DB13352
    Investigational

    It has been also used as an ingredient in skin care, and in cognitive function- and mood-enhancing products. … Deanol is commonly referred to as 2-(dimethylamino)ethanol, dimethylaminoethanol (DMAE) or dimethylethanolamine (DMEA). It holds tertiary amine and primary alcohol groups as functional groups.

  10. Drug

    Sulfacytine

    go.drugbank.com/drugs/DB01298
    Approved

    Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. … It inhibits bacterial synthesis of of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase.